Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by samtheshamon Mar 23, 2020 4:06pm

212 Views

Post# 30839059

Is this new drug going to be an ACE2 inhibitor or stimulator

Currently all NSAIDS except acetominaphen (Tylenol) are unsafe for use with COVID 19 as they stimulate production of ACE2s. Increased ACE2s allow the COVID 19 to easily enter our cells. NSAIDS not to be used include naproxen (Aleve etc) and ibuprofen (Aadvil etc). Does anyone know if this new drug is an ACE2 stimulator (bad) or an inhibitor (good)?

Bullboard Posts

Canadian government approves Glencore’s takeover of Teck’s coal business